Condensed Statements of Operations - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Operating expenses:
Research and development (net of collaboration funding of $718,410 and $2,999,371 in the three months ended March 31, 2023 and 2022 respectively)	$ 2,421,120	$ 3,171,639
General and administrative (net of collaboration funding of $1,142,596 and $2,372,175 in the three months ended March 31, 2023 and 2022 respectively)	2,568,181	3,875,601
Total operating expenses	4,989,301	7,047,240
Loss from operations	(4,989,301)	(7,047,240)
Other income (expense), net:
Costs of debt issuance	(577,225)	(1,168,065)
Loss on extinguishment of debt	(8,191,494)
Changes in fair value of debt instruments gain (loss)	(2,211,685)	(962,400)
Interest and other income (expense), net	(286,537)	(2,838)
Foreign currency transaction (loss) gain	(24,464)	1,539
Total other income (expense), net	(11,291,405)	(2,131,764)
Net loss	$ (16,280,706)	$ (9,179,004)
Net loss per share - basic	$ (0.77)	$ (0.64)
Weighted average common shares outstanding - basic	21,113,166	14,310,244
Net loss per share - diluted	$ (0.77)	$ (0.64)
Weighted average common shares outstanding - diluted	21,113,166	14,310,244